ArticleLung2026
Identification of ZNF331 as a Biomarker for Obstructive Sleep Apnea in Idiopathic Pulmonary Fibrosis Through Integrated Bioinformatics Analysis and Clinical Validation.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) is highly prevalent in patients with idiopathic pulmonary fibrosis (IPF), yet symptom-based screening frequently lacks reliability in this population. We aimed to identify a blood-based biomarker for detecting OSA in patients with IPF.
methodsPublic peripheral-blood transcriptomic datasets for OSA and IPF were analyzed to identify shared candidate genes. The leading candidate, ZNF331, was validated by reverse transcription-quantitative polymerase chain reaction in an independent clinical cohort comprising normal controls, patients with OSA, and non-oxygen-dependent patients with IPF. Diagnostic performance was assessed using receiver operating characteristic analysis and further corroborated through adjusted and internal validation analyses.
resultsZNF331 was prioritized as a shared candidate gene through the integrated bioinformatics analysis and was subsequently selected for clinical validation. In the validation cohort, ZNF331 expression exhibited an overall downward trend across the normal control, OSA, IPF, and IPF + OSA groups, reaching its lowest levels in patients with IPF complicated by OSA. ZNF331 demonstrated high diagnostic accuracy in differentiating IPF + OSA from IPF-only cases (area under the curve = 0.932, 95% confidence interval 0.874-0.990), whereas the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale showed limited diagnostic utility. The association between reduced ZNF331 expression and the IPF-OSA phenotype remained robust after propensity score matching and internal validation.
conclusionsZNF331 is a promising candidate blood-based biomarker for identifying OSA in patients with IPF. Its association with the IPF-OSA phenotype is supported by transcriptomic discovery, clinical validation, and robustness analyses. These findings suggest that ZNF331 may serve as a valuable screening biomarker for this population.
Indexed as
Identifiers
42573796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.